As the Omicron subvariants BA.4 and BA.5 continue to make viral waves, pharmaceutical companies are revamping their booster shots. Last week, Pfizer and its German-based partner BioNTech applied to the U.S. Food and Drug Administration for emergency use authorization for its booster jab targeting the original SARS-CoV-2 strain (which emerged at the pandemic’s outset) and the Omicron sublineages. Moderna has also tossed its reformulated jab into the approval ring.
